John S. Strader

906 citations
7 papers · 706 · 1 hit paper · h-index 4

Impact in

  • Hematology top 2%
    • Multiple Myeloma Research and Treatments
  • Oncology top 10%
    • Peptidase Inhibition and Analysis
    • Cancer-related Molecular Pathways

Papers in

    • Protein Degradation and Inhibitors 5
    • Ubiquitin and proteasome pathways 4
    • Histone Deacetylase Inhibitors Research 3
    • Multiple Myeloma Research and Treatments 6

John S. Strader

7 papers receiving 689 citations

Hit Papers

Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma 2007 · 591 citations
5910+6+12Years since publication100200300400500

Peers

John S. Strader
Comparison fields: 5 of 60
  • Hematology 384
  • Oncology 275
  • Molecular Biology 582
  • Genetics 54
  • Cancer Research 40
Replace Tina M. Woo with:
Tina M. Woo United States
Denise Niewerth Netherlands
K. Martin Kortuem United States
Soraya Wuillème‐Toumi France
Jana L. Dawson United States
Emmanuelle Ménoret France
Terry J. Gaymes United Kingdom
Maria Alessandra Santucci Italy
Nelida Sjak-Shie United States
YT Tai United States
John S. Strader relative to Tina M. Woo United States Tina M. Woo's profile →
Citations per field
00.5×1.7×
Tina M. Woo · 1×
Citations per year

Countries citing papers authored by John S. Strader

Since Specialization
Citations

This map shows the geographic impact of John S. Strader's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John S. Strader with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John S. Strader more than expected).

Fields of papers citing papers by John S. Strader

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John S. Strader. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John S. Strader. The network helps show where John S. Strader may publish in the future.

Co-authors

The 25 scholars most cited alongside John S. Strader, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with John S. Strader Line = papers co-authored together John S. Strader links everyone, so they are left out of the graph.

All Works

7 of 7 papers shown
#Work
1
Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma
Hit paper breakdown →
2007591
2 200793
3 20109
4 20096
5 20113
6 20053
7 20061

About John S. Strader

John S. Strader is a scholar working on Molecular Biology, Hematology, Oncology, Infectious Diseases and Organic Chemistry, having authored 7 papers that have together received 706 indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (6 papers), Protein Degradation and Inhibitors (5 papers), Ubiquitin and proteasome pathways (4 papers), Histone Deacetylase Inhibitors Research (3 papers) and Peptidase Inhibition and Analysis (1 paper). The work is most often cited by research in Hematology (384 citations), Oncology (275 citations), Molecular Biology (582 citations), Genetics (54 citations) and Cancer Research (40 citations). John S. Strader has collaborated with scholars based in United States, Germany and Netherlands. Frequent co-authors include Robert Z. Orlowski, Peter M. Voorhees, Deborah J. Kuhn, Qing Chen, Kevin D. Shenk, Congcong Sun, Susan D. Demo, Asher Chanan‐Khan, Fijs W. B. van Leeuwen and Mark K. Bennett. Their work appears in journals such as Blood and Clinical Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact